{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:13:23Z","timestamp":1781619203124,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000098","name":"National Institutes of Health Clinical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The current era of multiparametric prostate MRI (mpMRI) and ultrasound (US)\/ MRI fusion has improved early detection of clinically significant prostate cancer (csPCa) while decreasing the number of unnecessary biopsies. Hence, this study aims to define the diagnostic value of pre-biopsy digital rectal examination (DRE) for screening and detection of csPCa, when there is access to mpMRI and prostate-specific antigen (PSA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, single-center study involved 3379 consecutive patients biopsied between 2012 and 2023 using both MRI\/US-targeted fusion and systematic approaches. Biopsies were indicated because of elevated PSA levels and\/or presence of cancer suspicious lesions on MRI. All patients underwent DRE and mpMRI prior to biopsy. csPCa was defined as Gleason grade group \u22652. Diagnostic performance of DRE for csPCa was compared to PSA and PSA density (PSAD) using receiver operating characteristic curves.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Two thousand one hundred eighty-eight (65%) patients were diagnosed with PCa and 1498 (44%) patients with csPCa. DRE was positive in 410\/3379 (12%) patients. 261\/410 (64%) DRE positive patients had confirmed csPCa, of which 160\/261 (61%) were located in immediate proximity to the rectum. mpMRI was positive for focal lesion(s) in 1494\/1498 (100%) csPCa patients. For csPCa detection, DRE had a sensitivity of 0.17, specificity of 0.92, a positive predictive value of 0.63 and a negative predictive value of 0.59. Compared to DRE (AUC 0.55 [CI95% 0.54, 0.56]), PSA (AUC 0.63 [CI95% 0.61, 0.64]) and PSAD (AUC 0.73 [CI95% 0.71, 0.74]) showed better csPCa prediction performance (both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pre-biopsy DRE was found to add little to no diagnostic value for the routine diagnostic workflow in a constrained setting when PSA and mpMRI are initial screening tools for patients with suspected csPCa.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-025-01936-y","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:24:33Z","timestamp":1763731473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Digital rectal exam vs. electronic \u201cdigitized\u201d prostate exam"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3019-5470","authenticated-orcid":false,"given":"Tabea","family":"Borde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Varble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kenigsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey A.","family":"Hazen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Saccenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Turkbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford J.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"1936_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49.","DOI":"10.3322\/caac.21820"},{"key":"1936_CR2","unstructured":"U.S. Preventive Services Task Force. Prostate Cancer: Screening, Final Research Plan. 2023. Access date: May 22, 2024. Available from: https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/document\/final-research-plan\/prostate-cancer-screening-adults."},{"issue":"2","key":"1936_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00345-011-0804-y","volume":"30","author":"MJ Roobol","year":"2012","unstructured":"Roobol MJ, Schr\u00f6der FH, Hugosson J, Jones JS, Kattan MW, Klein EA, et al. Importance of prostate volume in the European randomised study of screening for prostate cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol. 2012;30(2):149\u201355.","journal-title":"World J Urol"},{"issue":"2","key":"1936_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1370\/afm.2205","volume":"16","author":"N Leen","year":"2018","unstructured":"Leen N, Harkanwal R, Zahra S, Brittany D, Deanna L, Owen K, et al. Digital rectal examination for prostate cancer screening in primary care: A systematic review and Meta-Analysis. Annals Family Med. 2018;16(2):149.","journal-title":"Annals Family Med"},{"issue":"4","key":"1936_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.juro.2017.10.021","volume":"199","author":"JA Halpern","year":"2018","unstructured":"Halpern JA, Oromendia C, Shoag JE, Mittal S, Cosiano MF, Ballman KV, et al. Use of digital rectal examination as an adjunct to prostate specific antigen in the detection of clinically significant prostate cancer. J Urol. 2018;199(4):947\u201353.","journal-title":"J Urol"},{"issue":"2S","key":"1936_CR6","doi-asserted-by":"publisher","first-page":"S200","DOI":"10.1016\/j.juro.2016.10.073","volume":"197","author":"WJ Catalona","year":"2017","unstructured":"Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 2017;197(2S):S200-7.","journal-title":"J Urol"},{"issue":"9","key":"1936_CR7","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/pros.20759","volume":"68","author":"C Gosselaar","year":"2008","unstructured":"Gosselaar C, Kranse R, Roobol MJ, Roemeling S, Schr\u00f6der FH. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate. 2008;68(9):985\u201393.","journal-title":"Prostate"},{"issue":"3","key":"1936_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/bco2.69","volume":"2","author":"CM Chang","year":"2021","unstructured":"Chang CM, McIntosh AG, Shapiro DD, Davis JW, Ward JF, Gregg JR. Does a screening digital rectal exam provide actionable clinical utility in patients with an elevated PSA and positive MRI? BJUI Compass. 2021;2(3):188\u201393.","journal-title":"BJUI Compass"},{"issue":"3","key":"1936_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.urology.2005.07.060","volume":"67","author":"J Philip","year":"2006","unstructured":"Philip J, Roy SD, Viswanathan P. Digital rectal examination is a barrier to population-based prostate cancer screening. Urology. 2006;67(3):655.","journal-title":"Urology"},{"issue":"6","key":"1936_CR10","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.urology.2004.12.021","volume":"65","author":"HM Nagler","year":"2005","unstructured":"Nagler HM, Gerber EW, Homel P, Wagner JR, Norton J, Lebovitch S, et al. Digital rectal examination is barrier to population-based prostate cancer screening. Urology. 2005;65(6):1137\u201340.","journal-title":"Urology"},{"issue":"11","key":"1936_CR11","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamainternmed.2020.3546","volume":"180","author":"P Hyman","year":"2020","unstructured":"Hyman P. The disappearance of the primary care physical examination\u2014losing touch. JAMA Intern Med. 2020;180(11):1417\u20138.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"1936_CR12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","volume":"382","author":"M Ahdoot","year":"2020","unstructured":"Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, et al. MRI-Targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med. 2020;382(10):917\u201328.","journal-title":"N Engl J Med"},{"issue":"15","key":"1936_CR13","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415\u201324.","journal-title":"N Engl J Med"},{"issue":"24","key":"1936_CR14","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1056\/NEJMoa1807801","volume":"379","author":"A Bill-Axelson","year":"2018","unstructured":"Bill-Axelson A, Holmberg L, Garmo H, Taari K, Busch C, Nordling S, et al. Radical prostatectomy or watchful waiting in prostate cancer \u2013 29-year follow-up. N Engl J Med. 2018;379(24):2319\u201329.","journal-title":"N Engl J Med"},{"issue":"2","key":"1936_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4103\/1117-6806.162570","volume":"21","author":"EI Udeh","year":"2015","unstructured":"Udeh EI, Dakum NK, Aderibigbe SA, Edeh JA. The utility of digital rectal examination in estimating prostate volume in a rural hospital setting. Niger J Surg. 2015;21(2):111\u20134.","journal-title":"Niger J Surg"},{"issue":"1","key":"1936_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32\u20135.","journal-title":"Cancer"},{"issue":"6","key":"1936_CR17","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.juro.2013.05.118","volume":"190","author":"A Walton Diaz","year":"2013","unstructured":"Walton Diaz A, Hoang AN, Turkbey B, Hong CW, Truong H, Sterling T, et al. Can magnetic resonance-ultrasound fusion biopsy improve cancer detection in enlarged prostates? J Urol. 2013;190(6):2020\u20135.","journal-title":"J Urol"},{"issue":"2","key":"1936_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3122\/jabfm.16.2.95","volume":"16","author":"K Mistry","year":"2003","unstructured":"Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract. 2003;16(2):95\u2013101.","journal-title":"J Am Board Fam Pract"},{"issue":"5","key":"1936_CR19","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1080\/21681805.2021.1966095","volume":"55","author":"V Soronen","year":"2021","unstructured":"Soronen V, Talala K, Raitanen J, Taari K, Tammela T, Auvinen A. Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9 ng\/ml: long-term results from a randomized trial. Scand J Urol. 2021;55(5):348\u201353.","journal-title":"Scand J Urol"},{"key":"1936_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.12.005","author":"A Matsukawa","year":"2024","unstructured":"Matsukawa A, Yanagisawa T, Bekku K, Kardoust Parizi M, Laukhtina E, Klemm J, et al. Comparing the performance of digital rectal examination and prostate-specific antigen as a screening test for prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2024. https:\/\/doi.org\/10.1016\/j.euo.2023.12.005.","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"1936_CR21","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/j.1464-410X.2011.10223.x","volume":"108","author":"JS Ko","year":"2011","unstructured":"Ko JS, Landis P, Carter HB, Partin AW. Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participants. BJU Int. 2011;108(11):1739\u201342.","journal-title":"BJU Int"},{"issue":"9","key":"1936_CR22","first-page":"e46012","volume":"15","author":"CB Richards","year":"2023","unstructured":"Richards CB, Corfield AB, Cleaveland P, Tang VC, Sinclair AN, Dyer JE. Evaluation of patients referred for abnormal digital rectal examination with normal prostate-specific antigen on best timed pathway for prostate cancer. Cureus. 2023;15(9):e46012.","journal-title":"Cureus"},{"issue":"14","key":"1936_CR23","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/pros.24203","volume":"81","author":"ZJ Prebay","year":"2021","unstructured":"Prebay ZJ, Medairos R, Doolittle J, Langenstroer P, Jacobsohn K, See WA, et al. The prognostic value of digital rectal exam for the existence of advanced pathologic features after prostatectomy. Prostate. 2021;81(14):1064\u201370.","journal-title":"Prostate"},{"key":"1936_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.urology.2020.08.089","volume":"147","author":"TFW Soeterik","year":"2021","unstructured":"Soeterik TFW, van Melick HHE, Dijksman LM, Biesma DH, Witjes JA, van Basten JA. Multiparametric magnetic resonance imaging should be preferred over digital rectal examination for prostate cancer local staging and disease risk classification. Urology. 2021;147:205\u201312.","journal-title":"Urology"},{"issue":"4","key":"1936_CR25","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.4103\/jcrt.jcrt_176_23","volume":"19","author":"J Zhu","year":"2023","unstructured":"Zhu J, Wu X, Xue Y, Li X, Zheng Q, Xue X, et al. Prospective analysis of the diagnostic accuracy of digital rectal examination and magnetic resonance imaging for T staging of prostate cancer. J Cancer Res Ther. 2023;19(4):1024\u201330.","journal-title":"J Cancer Res Ther"},{"key":"1936_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-024-01218-4","author":"L Shish","year":"2024","unstructured":"Shish L, Zabell J. Digital rectal exam in prostate cancer screening and elevated PSA work-up-is there a role anymore? Curr Urol Rep. 2024. https:\/\/doi.org\/10.1007\/s11934-024-01218-4.","journal-title":"Curr Urol Rep"},{"issue":"1","key":"1936_CR27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1080\/13685538.2020.1786047","volume":"24","author":"WS Tan","year":"2021","unstructured":"Tan WS, Wong A, Mahmalji W, Raza A. Is there still a role for digital rectal examination in the prostate cancer diagnostic pathway in the COVID-19 and post COVID-19 era? Aging Male. 2021;24(1):92\u20134.","journal-title":"Aging Male"},{"issue":"6","key":"1936_CR28","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.euo.2023.09.008","volume":"6","author":"A Krilaviciute","year":"2023","unstructured":"Krilaviciute A, Becker N, Lakes J, Radtke JP, Kuczyk M, Peters I, et al. Digital rectal examination is not a useful screening test for prostate cancer. Eur Urol Oncol. 2023;6(6):566\u201373.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"1936_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3109\/13685538.2010.522277","volume":"14","author":"AM Naccarato","year":"2011","unstructured":"Naccarato AM, Reis LO, Matheus WE, Ferreira U, Denardi F. Barriers to prostate cancer screening: psychological aspects and descriptive variables\u2014is there a correlation? Aging Male. 2011;14(1):66\u201371.","journal-title":"Aging Male"},{"issue":"7","key":"1936_CR30","first-page":"850","volume":"61","author":"FR Romero","year":"2008","unstructured":"Romero FR, Romero AW, Brenny Filho T, Bark NM, Yamazaki DS, de Oliveira FC. Patients\u2019 perceptions of pain and discomfort during digital rectal exam for prostate cancer screening. Arch Esp Urol. 2008;61(7):850\u20134.","journal-title":"Arch Esp Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01936-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01936-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01936-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:17:45Z","timestamp":1781615865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-025-01936-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1936"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01936-y","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Institutional Ethics Committee under the approval protocol number 12CC0075 - Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study. Patients signed informed consent regarding publishing their data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NV is an employee of Philips Healthcare. NIH co-authors had final control over the data analysis and content of the manuscript.Philips manufactures fusion navigation tools for ultrasound (PercuNav and UroNav), some of which were used in this study. NIH and Philips have a patent licensing agreement that pays royalties from Philips to NIH, a portion of which are then shared with BW. NIH (BW) has intellectual property in the field. BW Principal investigator has a cooperative research and development agreement (CRADA) between NIH and Philips and CRADAs with industry partners unrelated to this work; travel support related to CRADAs; royalties from NIH related to Philips licensing agreement; patents planned, issued, or pending. PAP Institutional CRADA with Philips; royalties from NIH related to Philips licensing agreement; NIH-related patents planned, issued, or pending (U.S. patent nos. 8 447 384 and 10 215830). BT has a CRADA with NVIDIA and Philips. The other authors have no conflict of interest to declare.Philips manufactures fusion navigation tools for ultrasound (PercuNav and UroNav), some of which were used in this study. NIH and Philips have a patent licensing agreement that pays royalties from Philips to NIH, a portion of which are then shared with BW. NIH (BW) has intellectual property in the field. BW Principal investigator has a cooperative research and development agreement (CRADA) between NIH and Philips and CRADAs with industry partners unrelated to this work; travel support related to CRADAs; royalties from NIH related to Philips licensing agreement; patents planned, issued, or pending. PAP Institutional CRADA with Philips; royalties from NIH related to Philips licensing agreement; NIH-related patents planned, issued, or pending (U.S. patent nos. 8 447 384 and 10 215830). BT has a CRADA with NVIDIA and Philips. The other authors have no conflict of interest to declare.Unrelated to this work, NIH has Cooperative Research & Development Agreements (BW is Principal Investigator) with the following: Celsion Corp, BTG Biocompatibles\/Boston Scientific, Siemens, NVIDIA, XAct Robotics, MediView.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}